TP53 Y220C occurs in 0.7% of NSCLC and more often in EGFR-mutant tumours, in an ETOP study of 28,244 patients
Read the article

Maastricht University Medical Center+ (Maastricht UMC+), Maastricht
Prof. Lizza E.L. Hendriks is a full professor of personalized diagnosis and treatment of lung cancer at Maastricht University and a pulmonologist specialized in thoracic oncology at Maastricht University Medical Center+ in Maastricht, the Netherlands. Her research focuses on brain metastases in lung cancer, neurocognition, oligometastatic and locally advanced NSCLC and SCLC, immunotherapy and targeted therapy. She is principal investigator in numerous phase II and III trials, lead author of the ESMO Clinical Practice Guidelines on metastatic NSCLC, and leads the Innovative Cancer Diagnostics Therapy group at the GROW research institute. She is a frequent speaker at major international thoracic oncology congresses.
Lizza Hendriks
Programme Roster